Every S-1 that CTT PHARMACEUTICAL HLDGS (CTTH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow CTTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTTH filings page.
CTT Pharmaceutical Holdings, Inc. is registering up to 6,250,000 shares of common stock for resale by RH2 Equity Partners under an equity line of credit. These are secondary sales by the investor; the company will not receive cash from resales of these shares.
The equity line allows CTT to sell up to $10,000,000 of stock to RH2 at 85% of the lowest daily VWAP over 10 trading days, subject to a 4.99% beneficial ownership cap. Common shares outstanding were 59,722,232, and would be 65,972,232 if all 6,250,000 shares are issued. Management currently plans to draw no more than $1,000,000 under the facility unless the share price exceeds $1.00, aiming to limit dilution.
The company develops patented fast-dissolving oral strips for drugs, nutraceuticals and nicotine, and plans to prioritize approximately $500,000 of equity-line proceeds for in house manufacturing equipment and related scale-up, focusing first on nicotine and vitamin products. CTT is a development-stage business with no recent revenues, reported net losses of $250,229 in 2024 and $155,907 in 2025, minimal cash of $7,089 as of March 31, 2026, and an auditor going concern qualification, and highlights significant regulatory, financing, volatility and dilution risks.
CTT Pharmaceutical Holdings, Inc. has filed an amended Form S-1 to register up to 6,250,000 shares of common stock for resale by RH2 Equity Partners under an Equity Line of Credit Agreement. This is a resale registration; CTT is not selling shares in this offering and will not receive proceeds from RH2’s sales. Separately, CTT may sell up to $10,000,000 of stock to RH2 over 24 months at 85.0% of the lowest daily VWAP over a 10‑day period, subject to a 4.99% Beneficial Ownership Cap.
Common shares outstanding are 59,722,232, rising to 65,972,232 if all registered shares are issued. CTT plans to initially draw about $1 million under the ELOC, prioritizing roughly $500,000 for in‑house manufacturing equipment and additional funds for nicotine and vitamin strip commercialization. The company reported losses of $250,229 in 2024 and $155,907 in 2025, and auditors have included a going‑concern qualification. CTT develops patented fast‑dissolving oral strips for pharmaceuticals, nutraceuticals, and nicotine, with near‑term focus on nicotine and vitamin products.
CTT Pharmaceutical Holdings, Inc. filed an S-1 amendment to register 6,250,000 shares of common stock for resale by RH2 Equity Partners under an equity line of credit. CTT is not selling shares in this prospectus and will not receive proceeds from RH2’s resales.
Under the Equity Line of Credit Agreement, CTT may sell up to $10,000,000 of stock to RH2 over 24 months, at 85% of the lowest 10‑day VWAP, subject to a 4.99% beneficial ownership cap. The company plans initially to draw about $1 million, targeting roughly $500,000 for in‑house manufacturing equipment and other working capital needs.
CTT focuses on fast‑dissolving oral strip technology for pharmaceuticals, nutraceuticals, nicotine and vitamins, but remains a development‑stage issuer with recent annual losses and a going‑concern warning. The filing highlights significant dilution risk from the ELOC, limited revenue to date, extensive regulatory requirements for nicotine products, and volatility risks associated with its OTCQB‑quoted, penny‑stock shares.
CTT Pharmaceutical Holdings, Inc. filed an amended Form S-1 to register up to 6,250,000 shares of common stock for resale by RH2 Equity Partners under an Equity Line of Credit (ELOC). CTT will not receive proceeds from these resales, but can sell shares directly to RH2 for up to $10,000,000 in potential funding over 24 months.
The company focuses on fast-dissolving oral strip technology for pharmaceuticals, nutraceuticals, nicotine and vitamins, with initial commercialization aimed at nicotine and vitamin strips. CTT is a development-stage business with recent annual net losses and a going-concern warning, and highlights significant dilution and penny-stock risks tied to use of the ELOC.
CTT Pharmaceutical Holdings, Inc. is registering 6,250,000 shares of common stock for resale by RH2 Equity Partners under an equity line of credit arrangement. These shares relate to an up to $10,000,000 equity line, where RH2 buys stock at 85% of the lowest 10-day VWAP, subject to a 4.99% beneficial ownership cap.
CTT will not receive proceeds from RH2’s resale of shares, but may receive cash when it sells stock to RH2 under the line. As of December 11, 2025, 58,712,232 shares were outstanding, and issuing all registered shares would raise this to 69,678,898. The company plans initially to use up to $1,000,000 from the facility, prioritizing about $500,000 for in‑house manufacturing equipment and paying roughly $2,000 per month for production space.
CTT is a development-stage drug delivery company focused on fast-dissolving oral strips for pharmaceuticals, nutraceuticals, nicotine and vitamins, with a history of losses and a going concern qualification. Management highlights significant regulatory, commercialization, dilution and penny stock risks, and notes that common stock traded at $0.0825 per share on the OTCQB on May 26, 2026.
CTT Pharmaceutical Holdings, Inc. has filed an amended Form S-1 to register up to 6,250,000 shares of common stock for resale by RH2 Equity Partners, the selling stockholder under an equity line of credit agreement. The company is not selling shares in this offering and will not receive proceeds from RH2’s resales, though it may raise up to $10,000,000 by selling shares directly to RH2 over a 24‑month period under the ELOC.
CTT focuses on fast‑dissolving oral drug delivery strips for pharmaceuticals, nutraceuticals and nicotine. It is a development-stage company with limited revenues, recent annual losses and a going concern qualification. The filing highlights significant regulatory, financing, dilution and penny‑stock risks, as well as dependence on future FDA processes for nicotine strips and on additional capital, including the equity line.